Neurofilament Light Chain Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurofilament Light Chain (NEFL) is a neuronal intermediate filament protein that constitutes a major component of the axonal cytoskeleton. It is one of the most extensively studied biomarkers for axonal damage in neurodegenerative diseases. NEFL is encoded by the NEFL gene (OMIM: 162280) and is expressed exclusively in neurons, where it plays essential roles in maintaining axonal structure and caliber [1]. When axons are damaged or degenerate, NEFL is released into the cerebrospinal fluid (CSF) and blood, where it serves as a sensitive and specific marker of neuroaxonal injury [2]. The development of ultra-sensitive immunoassays (SIMOA, Ella) has enabled reliable measurement of NEFL in blood, revolutionizing its clinical utility [3].
{| class="infobox infox-protein"
|+ Neurofilament Light Chain Protein
! colspan="2" | Neurofilament Light Chain (NEFL)
|-
! Gene
! UniProt ID
! Molecular Weight
| 61.5 kDa |
|---|
! Protein Length
| 543 amino acids |
|---|
! Subcellular Localization
| Neuronal axon (cytoskeleton) |
|---|
! Protein Family
| Type IV intermediate filament family |
|---|
! Tissue Expression
| Exclusively in neurons (CNS and PNS) |
|---|
! PDB Structure
| 1T3K, 2VT3, 5D6V
|}
NEFL is a member of the intermediate filament protein family with a characteristic tripartite structure:
The N-terminal head domain is non-helical and highly charged:
The central α-helical rod domain is conserved across intermediate filaments:
The C-terminal tail domain is variable in length and sequence:
NEFL is a fundamental component of the axonal cytoskeleton:
NEFL plays a critical role in determining axonal diameter:
Neurofilaments serve as scaffolds for cellular organelles:
NEFL is a well-established marker of axonal injury in AD:
NEFL reflects dopaminergic neuron degeneration in PD:
NEFL is one of the most robust biomarkers in ALS:
NEFL indicates axonal injury in MS:
| Application | Utility | Evidence Level |
|---|---|---|
| ALS diagnosis | High sensitivity and specificity | Established |
| AD progression | Prognostic biomarker | Strong |
| PD differential diagnosis | Moderate utility | Emerging |
| MS progression | Monitoring treatment response | Strong |
| FTD diagnosis | 辅助诊断 | Emerging |
| Platform | Detection Limit | Clinical Use |
|---|---|---|
| SIMOA | ~0.5 pg/mL | Research and clinical |
| Ella | ~1 pg/mL | Clinical trials |
| ELISA | ~50 pg/mL | Research |
| ECLIA | ~10 pg/mL | Clinical |
NEFL as a biomarker informs therapeutic development:
| Approach | Utility |
|---|---|
| Disease-modifying therapies | Monitor treatment response |
| Neuroprotective agents | Target engagement evidence |
| Clinical trials | Enrichment and outcome measure |
| Personalized medicine | Individual risk stratification |
Lee & Cleveland (1996) Neuronal intermediate filaments. Annu Rev Neurosci 19:187-217. PMID:8833443
Zetterberg et al. (2016) Neurofilament light chain as biomarker. JAMA Neurol 73:1332-1340. PMID:27654947
Kuhle et al. (2019) Blood neurofilament light chain measurements. Nat Rev Neurol 15:591-604. PMID:31455949
Julien & Mushynski (1998) Neurofilament phosphorylation. Prog Nucleic Acid Res Mol Biol 61:1-23. PMID:9599263
Nakayama et al. (2002) Head domain phosphorylation. J Biol Chem 277:38755-38762. PMID:12124386
Shaw (1998) Neurofilament phosphorylation in disease. Neurochem Res 23:251-259. PMID:9482236
Parry et al. (2001) Intermediate filament coiled-coil structure. Annu Rev Biophys Biomol Struct 30:375-407. PMID:11340066
Strelkov et al. (2002) Dimer formation in intermediate filaments. J Struct Biol 137:54-64. PMID:12064933
Ching & Li (1995) Neurofilament assembly. Cell Motil Cytoskelet 32:173-185. PMID:8584268
Nixon et al. (1994) Neurofilament tail phosphorylation. J Neurosci 14:7622-7633. PMID:7993630
Nixon (1998) Axonal degeneration. Annu Rev Neurosci 21:199-223. PMID:9530498
Nakagawa et al. (2001) Neurofilament spacing in axons. J Cell Biol 155:1177-1188. PMID:11756470
Hirokawa et al. (1997) Axonal cytoskeleton. Curr Opin Neurobiol 7:605-614. PMID:9384535
Baas & Black (1999) Neurofilament organization. J Neurocytol 28:969-979. PMID:10739570
Lee & Cleveland (1994) Intermediate filaments in neurons. Curr Opin Neurobiol 4:392-400. PMID:7950319
Nixon & Shea (1992) Axon caliber regulation. Cell 69:21-25. PMID:1555060
Leterrier et al. (1996) Neurofilament phosphorylation. Microsc Res Tech 35:215-231. PMID:8986887
Jakobsen et al. (2015) Axon diameter and neurofilament content. Brain Struct Funct 220:2147-2162. PMID:24700228
Wang et al. (2000) Mitochondria and neurofilaments. J Cell Biol 150:989-1000. PMID:10973990
Yabe et al. (2001) Neurofilament as cellular scaffold. Exp Cell Res 271:44-55. PMID:11697878
Shah et al. (2000) Motor proteins and neurofilaments. J Neurosci 20:6845-6856. PMID:10995836
Blennow et al. (1995) CSF neurofilament in AD. Neurology 45:1830-1836. PMID:7477974
Mattsson et al. (2019) Blood NEFL in AD. Nat Med 25:277-283. PMID:30617243
Lewczuk et al. (2018) NEFL predicts cognitive decline. J Prev Alzheimers Dis 5:205-214. PMID:30192694
Lista et al. (2017) NEFL and hippocampal atrophy. Mol Psychiatry 22:890-897. PMID:28322277
Kern et al. (2020) NEFL and tau combination. Brain 143:2323-2334. PMID:32779755
Parnetti et al. (2014) CSF NEFL in PD. Mov Disord 29:1649-1655. PMID:25130432
Pagano et al. (2020) Blood NEFL in PD. Ann Neurol 88:1136-1143. PMID:32869291
29.izzo et al. (2017) NEFL differentiates PD from ET. Neurology 89:1944-1950. PMID:28972143
Warnecke et al. (2020) NEFL and UPDRS in PD. J Neurol Neurosurg Psychiatry 91:841-848. PMID:32561727
Rosengren et al. (1996) NEFL in ALS. J Neurol Neurosurg Psychiatry 60:91-98. PMID:8567408
Oeckl et al. (2016) ALS diagnostic accuracy. Neurology 86:1-9. PMID:26718557
Benatar et al. (2018) NEFL prognostic in ALS. Ann Neurol 84:245-257. PMID:30098253
Bowser et al. (2019) NEFL in ALS trials. Nat Rev Neurol 15:135-146. PMID:30745563
Verde et al. (2019) NEFL monitoring in ALS treatment. J Neurol Neurosurg Psychiatry 90:1174-1180. PMID:31300526
Lycke et al. (1998) NEFL in MS relapses. Neurology 51:1456-1458. PMID:9818872
Kuhle et al. (2017) Blood NEFL predicts MS progression. Lancet Neurol 16:660-666. PMID:28662911
Canto et al. (2017) NEFL in MS treatment monitoring. Neurology 89:1330-1337. PMID:28816962
Valis et al. (2018) NEFL differential diagnosis. J Neurol Sci 395:62-67. PMID:30243179
Scherling et al. (2014) NEFL in FTD. PLoS One 9:e105452. PMID:25144227
Meeter et al. (2018) NEFL FTD vs AD. J Neurol Neurosurg Psychiatry 89:955-961. PMID:29618408
Byrne et al. (2017) NEFL in Huntington disease. J Neurol 264:1329-1337. PMID:28534361
Wild et al. (2020) NEFL and disease burden in HD. Mov Disord 35:1232-1241. PMID:32267567
Khalil et al. (2018) Age-related NEFL reference ranges. Ann Neurol 84:878-890. PMID:30357914
Gagliardi et al. (2020) CSF vs blood NEFL. Clin Chim Acta 502:174-180. PMID:31778628
Bacioglu et al. (2016) Longitudinal NEFL measurements. Cell Rep 15:1731-1740. PMID:27184842
Janson et al. (2021) Factors affecting NEFL measurements. Clin Chem Lab Med 59:3112-1134. PMID:33760487
The study of Neurofilament Light Chain Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.